Pazufloxacin mesylate

Base Information

• Chemical Name: Pazufloxacin mesylate
• CAS No.: 163680-77-1
• Molecular Formula: C16H15FN2O4.CH4O3S
• Molecular Weight: 414.41
• Hs Code.: 29349990
• European Community (EC) Number: 634-946-6
• NSC Number: 759831
• UNII: 2XI226J1HS
• DSSTox Substance ID: DTXSID80167645
• Wikidata: Q27255767
• Mol file: 163680-77-1.mol

Synonyms:T 3762;T-3762

Chemical Property of Pazufloxacin mesylate

Chemical Property:

• Appearance/Colour: crystalline solid
• Vapor Pressure: 4E-12mmHg at 25°C
• Melting Point: >255 °C (dec.)
• Boiling Point: 531.5 °C at 760 mmHg
• Flash Point: 275.2 °C
• PSA: 157.30000
• LogP: 3.02510
• Storage Temp.: -20°C Freezer
• Solubility.: Aqueous Base (Slightly), DMSO (Slightly)
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 10
• Rotatable Bond Count: 2
• Exact Mass: 414.08970028
• Heavy Atom Count: 28
• Complexity: 695

Purity/Quality:

99% ^*data from raw suppliers

Pazufloxacin mesylate ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xi,C,F
• Hazard Codes: Xi,C,F
• Statements: 36/37/38-34-11
• Safety Statements: 26-45-36/37/39-16

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C(=O)O.CS(=O)(=O)O
• Isomeric SMILES: C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2C4(CC4)N)F)C(=O)O.CS(=O)(=O)O
• Recent ClinicalTrials: Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol
• Recent NIPH Clinical Trials: None
• Description: This fluoroquinolone was co-developed by Toyama and Mitsubishi Pharm and was launched for the intravenous therapy of respiratory, urinary, surgical, gynecological and systemic infections. Pazufloxacin is a broad-spectrum synthetic fluoroquinolone antibiotic. It is active against Gram-negative and Gram-positive bacteria, including clinical isolates of E. coli, K. pneumoniae, methicillin-susceptible and -resistant S. aureus, and methicillin-susceptible and -resistant S. epidermidis (MIC90s = 0.05, 0.1, 0.39, 12.5, 0.39, and 6.25 μg/ml, respectively). It inhibits E. coli, P. aeruginosa, and S. aureus DNA gyrase (IC50s = 0.88, 1.9, and 10.2 μg/ml, respectively) and S. aureus topoisomerase IV (IC50 = 24.2 μg/ml) in cell-free assays. In vivo, pazufloxacin is active against systemic E. coli, K. pneumoniae, and methicillin-resistant S. aureus infections in mice (ED50s = 0.15, 5.5, and 4.5 mg/kg, respectively).
• Uses: A fluorinated quinolone antibiotic. Antibacterial.